Omega-3s and the Tear Film Equilibrium
The most clinically significant document in eye health is the AREDS2 (Age-Related Eye Disease Study 2) formulation. In 2026, it remains the primary recommendation for individuals with intermediate to advanced Age-Related Macular Degeneration (AMD).
The Formulation: A high-dose combination of Vitamin C (500 mg), Vitamin E (400 IU), Zinc (80 mg), Copper (2 mg), Lutein (10 mg), and Zeaxanthin (2 mg).
Key 2026 Update: Recent longitudinal data indicates that the AREDS2 formula can slow the loss of central vision in patients with geographic atrophy (advanced dry AMD) by as much as 35%.
Safety Note: By 2026, Beta-carotene has been completely phased out of most ocular supplements because it increases lung cancer risk in smokers; it has been replaced by Lutein and Zeaxanthin.